HemoGenyx Pharmaceuticals PLC’s (LON:HEMO) Immugenyx subsidiary is teaming up with US pharma giant Johnson & Johnson to find a new treatment for lupus.
Under the terms of the collaboration agreement with J&J’s Janssen division, Immugenyx will use its advanced hematopoietic chimeras (AHC) to develop a lupus disease model in a humanised mouse with a functional human immune system.
For the full article please click here.
